Other OTC - Delayed Quote • USD
Fresh Tracks Therapeutics, Inc. (FRTX)
At close: April 23 at 2:10 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
8,006.0000
8,006.0000
6,943.0000
404.0000
1,822.0000
Operating Expense
14,366.0000
14,366.0000
28,477.0000
40,648.0000
22,798.0000
Operating Income
-6,360.0000
-6,360.0000
-21,534.0000
-40,244.0000
-20,976.0000
Net Non Operating Interest Income Expense
-5.0000
-5.0000
-9.0000
-69.0000
--
Other Income Expense
671.0000
671.0000
441.0000
839.0000
63.0000
Pretax Income
-5,694.0000
-5,694.0000
-21,102.0000
-39,474.0000
-20,913.0000
Net Income Common Stockholders
-5,694.0000
-5,694.0000
-21,102.0000
-39,474.0000
-20,913.0000
Diluted NI Available to Com Stockholders
-5,694.0000
-5,694.0000
-21,102.0000
-39,474.0000
-20,913.0000
Basic EPS
-1.06
--
-7.51
-22.12
-38.25
Diluted EPS
-1.06
--
-7.51
-22.12
-38.25
Basic Average Shares
5,394.5510
--
2,808.0750
1,784.7910
544.7590
Diluted Average Shares
5,394.5510
--
2,808.0750
1,784.7910
544.7590
Total Operating Income as Reported
-6,360.0000
-6,360.0000
-21,534.0000
-40,244.0000
-20,976.0000
Total Expenses
14,366.0000
14,366.0000
28,477.0000
40,648.0000
22,798.0000
Net Income from Continuing & Discontinued Operation
-5,694.0000
-5,694.0000
-21,102.0000
-39,474.0000
-20,913.0000
Normalized Income
-5,694.0000
-5,694.0000
-21,102.0000
-39,474.0000
-20,976.0000
Interest Expense
5.0000
5.0000
9.0000
69.0000
--
Net Interest Income
-5.0000
-5.0000
-9.0000
-69.0000
--
EBIT
-5,689.0000
-5,689.0000
-21,093.0000
-39,405.0000
-20,913.0000
EBITDA
-5,648.0000
-5,648.0000
-21,063.0000
-39,383.0000
-20,903.0000
Reconciled Depreciation
41.0000
41.0000
30.0000
22.0000
10.0000
Net Income from Continuing Operation Net Minority Interest
-5,694.0000
-5,694.0000
-21,102.0000
-39,474.0000
-20,913.0000
Total Unusual Items Excluding Goodwill
--
--
--
839.0000
63.0000
Total Unusual Items
--
--
--
839.0000
63.0000
Normalized EBITDA
-5,648.0000
-5,648.0000
-21,063.0000
-39,383.0000
-20,966.0000
12/31/2020 - 3/10/1993
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CYTT Cyteir Therapeutics, Inc.
3.0100
-0.33%
SLGL Sol-Gel Technologies Ltd.
0.9252
+0.41%
QNRX Quoin Pharmaceuticals, Ltd.
0.6600
0.00%
SQZB SQZ Biotechnologies Company
0.0465
0.00%
FAMDF Futura Medical plc
0.4000
-5.21%
SCPS Scopus BioPharma Inc.
0.0016
0.00%
CTCX Carmell Corporation
2.2000
+15.18%
PYPD PolyPid Ltd.
4.4845
-0.12%
CELZ Creative Medical Technology Holdings, Inc.
4.8201
+0.00%
AEZS.TO Aeterna Zentaris Inc.
2.6600
0.00%